Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy NexImmune stock | $12.88

Learn how to easily invest in NexImmune stock.

NexImmune Inc
NASDAQ: NEXI - USD
BIOTECHNOLOGY
$12.88
0.00%

NexImmune Inc is a biotechnology business based in the US. NexImmune shares (NEXI) are listed on the NASDAQ and all prices are listed in US Dollars. NexImmune employs 44 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in NexImmune

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – NEXI – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

NexImmune stock price (NASDAQ: NEXI)

Use our graph to track the performance of NEXI stocks over time.

NexImmune shares at a glance

Information last updated 2021-10-24.
Latest market close$12.88
52-week range$10.10 - $28.00
50-day moving average $14.58
200-day moving average $15.53
Wall St. target price$33.33
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-4.17

Buy NexImmune shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Robinhood
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
0%
N/A
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
N/A
$20 per year
N/A
Financial advice powered by relationships, not commissions.
TradeStation
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
$50
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Sofi Invest
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Moomoo
Stocks
$0
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy NexImmune stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

NexImmune price performance over time

Historical closes compared with the close of $12.88 from 2021-10-22

1 week (2021-10-18) 4.38%
1 month (2021-09-24) -21.27%
3 months (2021-07-25) -10.49%
6 months (2021-04-23) -33.74%
1 year (2020-10-21) N/A
2 years (2019-10-21) N/A
3 years (2018-10-21) N/A
5 years (2016-10-21) N/A

NexImmune financials

Gross profit TTM $0
Return on assets TTM -139.15%
Return on equity TTM 0%
Profit margin 0%
Book value $4.86
Market capitalisation $291.4 million

TTM: trailing 12 months

Shorting NexImmune shares

There are currently 595,674 NexImmune shares held short by investors – that's known as NexImmune's "short interest". This figure is 94.1% up from 306,905 last month.

There are a few different ways that this level of interest in shorting NexImmune shares can be evaluated.

NexImmune's "short interest ratio" (SIR)

NexImmune's "short interest ratio" (SIR) is the quantity of NexImmune shares currently shorted divided by the average quantity of NexImmune shares traded daily (recently around 158846.4). NexImmune's SIR currently stands at 3.75. In other words for every 100,000 NexImmune shares traded daily on the market, roughly 3750 shares are currently held short.

To gain some more context, you can compare NexImmune's short interest ratio against those of similar companies.

However NexImmune's short interest can also be evaluated against the total number of NexImmune shares, or, against the total number of tradable NexImmune shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case NexImmune's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 NexImmune shares in existence, roughly 30 shares are currently held short) or 0.0339% of the tradable shares (for every 100,000 tradable NexImmune shares, roughly 34 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against NexImmune.

Find out more about how you can short NexImmune stock.

NexImmune share dividends

We're not expecting NexImmune to pay a dividend over the next 12 months.

NexImmune overview

NexImmune, Inc. , a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; and NEXI-002, an autologous cell therapy, which is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland. .

Frequently asked questions

What percentage of NexImmune is owned by insiders or institutions?
Currently 27.409% of NexImmune shares are held by insiders and 43.181% by institutions.
How many people work for NexImmune?
Latest data suggests 44 work at NexImmune.
When does the fiscal year end for NexImmune?
NexImmune's fiscal year ends in December.
Where is NexImmune based?
NexImmune's address is: 9119 Gaither Road, Gaithersburg, MD, United States, 20877
What is NexImmune's ISIN number?
NexImmune's international securities identification number is: US65344D1090

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site